Celgene/Nippon Kayaku's Calsed Will Become Decision Resources' New Clinical Gold Standard in 2013 for the Treatment of Extensive-Disease Small-Cell Lung Cancer

Surveyed Oncologists Look for a Drug That Can Improve Median Overall Survival in Patients, According to a New Report from Decision Resources

Jan 18, 2010, 08:00 ET from Decision Resources

WALTHAM, Mass., Jan. 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Celgene/Nippon Kayaku's Calsed earns Decision Resources' proprietary clinical gold standard status in 2013 for the treatment of extensive-disease small-cell lung cancer, following its approval for the indication in 2012. Calsed has competitive advantages over other drugs used in the second-line setting in efficacy, safety and tolerability, and delivery.

"Calsed has already launched in Japan, and in lieu of Phase III trial results, Phase II data in Western populations comparing the agent with GlaxoSmithKline's Hycamtin (the only agent approved for small-cell lung cancer second-line treatment) are encouraging and show improved efficacy data," stated Decision Resources' Analyst Amy Duval, M.Res.

The new report entitled Extensive-Disease Small-Cell Lung Cancer: New Entrants Will Offer Only Incremental Improvements in Patient Outcomes also finds that a drug's effect on median overall survival is the drug attribute that most influences surveyed oncologists prescribing decisions in extensive-disease small-cell lung cancer. However, clinical data discussed in the report and interviewed key opinion leaders indicate that current and emerging drugs have a very small advantage over the patient share leader Bristol-Myers Squibb's Etopophos/VePesid, generics plus Bristol-Myers Squibb's Paraplatin, generics on this attribute.

About the Report

Extensive-Disease Small-Cell Lung Cancer: New Entrants Will Offer Only Incremental Improvements in Patient Outcomes is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development. 

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Decision Resources

Decision Resources, Inc.

Gisselle Morales

Elizabeth Marshall

781-296-2691

781-296-2563

gmorales@dresources.com

emarshall@dresources.com


SOURCE Decision Resources



RELATED LINKS

http://www.decisionresources.com